References

1. European Centre for Disease Prevention and Control (ECDC). Case definition for COVID-19, as of 3 December 2020. Stockholm: ECDC; 2020. Available at: https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition
2. WHO Regional Office for Europe, European Centre for Disease Prevention and Control (ECDC). Operational considerations for respiratory virus surveillance in Europe. Copenhagen and Stokholm: WHO Regional Office for Europe and ECDC, 2022
3. International Committee on Taxonomy of Viruses (ICTV). Virus Taxonomy: The Classification and Nomenclature of Viruses. The 9th Report of the ICTV. 2011. Available at: https://ictv.global/report_9th
4. European Centre for Disease Prevention and Control (ECDC). SARS-CoV-2 variants of concern Stockholm: ECDC; 2023. Available at: https://www.ecdc.europa.eu/en/covid-19/variants-concern
5. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. Journal of internal medicine. 2020 Sep;288(3):335-44.
6. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morbidity and mortality weekly report. 2020 Jun 19;69(24):759-65.
7. Tong JY, Wong A, Zhu D, Fastenberg JH, Tham T. The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2020 Jul;163(1):3-11.
8. Aziz M, Perisetti A, Lee-Smith WM, Gajendran M, Bansal P, Goyal H. Taste Changes (Dysgeusia) in COVID-19: A Systematic Review and Meta-analysis. Gastroenterology. 2020 Sep;159(3):1132-3.
9. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2021 Dec;26(50)
10. Long B, Carius BM, Chavez S, Liang SY, Brady WJ, Koyfman A, et al. Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. The American journal of emergency medicine. 2022 Apr;54:46-57.
11. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020 Mar 17;323(11):1061-9.
12. Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research. 2020 Jul;191:145-7.
13. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nature medicine. 2022 Mar;28(3):583-90.
14. Bundle N, Dave N, Pharris A, Spiteri G, Deogan C, Suk JE, et al. COVID-19 trends and severity among symptomatic children aged 0–17 years in 10 European Union countries, 3 August 2020 to 3 October 2021. Eurosurveillance. 2021;26(50):2101098. Available at: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.50.2101098
15. Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. Jama. 2020;324(3):259-69. Available at: https://doi.org/10.1001/jama.2020.10369
16. Royal College of Paediatrics and Child Health (RCPCH). Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS) - guidance for clinicians. London: RCPCH; 2020. Available at: https://www.rcpch.ac.uk/resources/paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims-guidance
17. Yang J, Hu J, Zhu C. Obesity aggravates COVID-19: A systematic review and meta-analysis. Journal of medical virology. 2021 Jan;93(1):257-61.
18. Vardavas CI, Mathioudakis AG, Nikitara K, Stamatelopoulos K, Georgiopoulos G, Phalkey R, et al. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe. European respiratory review : an official journal of the European Respiratory Society. 2022 Dec 31;31(166)
19. Yekedüz E, Utkan G, Ürün Y. A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19. European journal of cancer (Oxford, England : 1990). 2020 Dec;141:92-104.
20. Gallus S, Scala M, Possenti I, Jarach CM, Clancy L, Fernandez E, et al. The role of smoking in COVID-19 progression: a comprehensive meta-analysis. European Respiratory Review. 2023;32(167):220191. Available at: https://err.ersjournals.com/content/errev/32/167/220191.full.pdf

21. Mazzalai E, Giannini D, Tosti ME, D'Angelo F, Declich S, Jaljaa A, et al. Risk of Covid-19 Severe Outcomes and Mortality in Migrants and Ethnic Minorities Compared to the General Population in the European WHO Region: a Systematic Review. Journal of international migration and integration. 2023 Jan 11:1-31.
22. World Health Organization (WHO). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Geneva: WHO; 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1
23. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nature medicine. 2021 2021/04/01;27(4):601-15. Available at: https://doi.org/10.1038/s41591-021-01283-z
24. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nature medicine. 2021 2021/04/01;27(4):626-31. Available at: https://doi.org/10.1038/s41591-021-01292-y
25. Zimmermann P, Pittet LF, Curtis N. How Common is Long COVID in Children and Adolescents? The Pediatric infectious disease journal. 2021 Dec 1;40(12):e482-e7.
26. World Health Organization (WHO). Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). Geneva: WHO; 2020. Available at: https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)
27. World Health Organization (WHO). WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Geneva: WHO; 2020. Available at: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
28. World Health Organization (WHO). Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. Geneva: WHO; 2023. Available at: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
29. European Centre for Disease Prevention and Control (ECDC). COVID-19 situation updates. Stockholm: ECDC; 2023. Available at: https://www.ecdc.europa.eu/en/covid-19/situation-updates
30. Rai B, Shukla A, Dwivedi LK. Incubation period for COVID-19: a systematic review and meta-analysis. Zeitschrift fur Gesundheitswissenschaften = Journal of public health. 2022;30(11):2649-56.
31. Qiu X, Nergiz AI, Maraolo AE, Bogoch, II, Low N, Cevik M. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission-a living systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021 Apr;27(4):511-9.
32. Mugglestone MA, Ratnaraja NV, Bak A, Islam J, Wilson JA, Bostock J, et al. Presymptomatic, asymptomatic and post-symptomatic transmission of SARS-CoV-2: joint British Infection Association (BIA), Healthcare Infection Society (HIS), Infection Prevention Society (IPS) and Royal College of Pathologists (RCPath) guidance. BMC Infectious Diseases. 2022 2022/05/12;22(1):453. Available at: https://doi.org/10.1186/s12879-022-07440-0
33. van Kampen JJA, van de Vijver D, Fraaij PLA, Haagmans BL, Lamers MM, Okba N, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nature communications. 2021 Jan 11;12(1):267.
34. Kissler SM, Fauver JR, Mack C, Tai CG, Breban MI, Watkins AE, et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons. The New England journal of medicine. 2021 Dec 23;385(26):2489-91.
35. Takahashi K, Ishikane M, Ujiie M, Iwamoto N, Okumura N, Sato T, et al. Duration of Infectious Virus Shedding by SARS-CoV-2 Omicron Variant-Infected Vaccinees. Emerging infectious diseases. 2022 May;28(5):998-1001.
36. European Centre for Disease Prevention and Control (ECDC). Infection prevention and control and preparedness for COVID-19 in healthcare settings. Stockholm: ECDC; 2021. Available at: https://www.ecdc.europa.eu/en/publications-data/infection-prevention-and-control-and-preparedness-covid-19-healthcare-settings
37. World Health Organization (WHO). Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020. Geneva: WHO; 2020. Available at: https://apps.who.int/iris/handle/10665/331501

38. european Centre for Disease Prevention and Control (ECDC). COVID-19 testing strategies and objectives. ECDC; 2020. Available at: https://www.ecdc.europa.eu/en/publications-data/covid-19-testing-strategies-and-objectives
39. Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. The Journal of general virology. 2020 Aug;101(8):791-7.
40. World Health Organization (WHO). Therapeutics and COVID-19: Living guideline, 13 January 2023. Geneva: WHO; 2023. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.1
41. European Medicines Agency (EMA). COVID-19 treatments Amsterdam: EMA; 2023. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments
42. European Medicines Agency (EMA). COVID-19 vaccines Amsterdam: EMA; 2023. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines
43. Külper-Schiek W, Piechotta V, Pilic A, Batke M, Dreveton LS, Geurts B, et al. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. Frontiers in immunology. 2022;13:940562.
44. (COVID-END) C-ENtsD-m. Evidence about public-health measures. COVID-END; 2023. Available at: https://www.mcmasterforum.org/networks/covid-end/covid-end-inventory/public-health-measures
45. European Centre for Disease Prevention and Control (ECDC). Efficacy, effectiveness and safety of EU/EEA-authorised vaccines against COVID-19: living systematic review. Stockholm: ECDC; 2023. Available at: https://www.ecdc.europa.eu/en/covid-19-efficacy-effectiveness-and-safety-vaccines
46. International Vaccine Access Center (IVAC). VIEW-Hub Resource Library. IVAC; 2023. Available at: https://view-hub.org/resources
47. Wu N, Joyal-Desmarais K, Ribeiro PAB, Vieira AM, Stojanovic J, Sanuade C, et al. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. The Lancet Respiratory medicine. 2023 Feb 10
48. Williams J, Barratte S, Winfield T, Elston L, McDermott K, Jarrom D, et al. The effect of vaccination on transmission of SARS-CoV-2 (COVID-19): a rapid review. medRxiv [Preprint]. 13 December 2022 2022; Available at: https://www.medrxiv.org/content/10.1101/2022.12.09.22283255v1.article-info
49. European Medicines Agency (EMA). COVID-19 vaccines safety update. Amsterdam: EMA; 2022. Available at: https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccines-safety-update-8-december-2022_en.pdf
50. European Medicines Agency (EMA). Safety of COVID-19 vaccines. Amsterdam: EMA; 2023. Available at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/safety-covid-19-vaccines
51. Stein C, Nassereldine H, Sorensen RJD, Amlag JO, Bisignano C, Byrne S, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. The Lancet. 2023 2023/03/11/;401(10379):833-42. Available at: https://www.sciencedirect.com/science/article/pii/S0140673622024655
52. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. The Lancet Infectious Diseases. 2023 2023/05/01/;23(5):556-67. Available at: https://www.sciencedirect.com/science/article/pii/S1473309922008015
53. European Centre for Disease Prevention and Control (ECDC). Non-pharmaceutical interventions against COVID-19. Stockholm: ECDC; 2023. Available at: https://www.ecdc.europa.eu/en/covid-19/prevention-and-control/non-pharmaceutical-interventions
54. European Centre for Disease Prevention and Control (ECDC). Considerations for infection prevention and control practices in relation to respiratory viral infections in healthcare settings. Stockholm: ECDC; 2023. Available at: https://www.ecdc.europa.eu/en/publications-data/considerations-infection-prevention-and-control-practices-relation-respiratory